Alva, Ajjai

Integrative clinical genomics of metastatic cancer

Robinson, D. R., Wu, Y.-M., Lonigro, R. J., Vats, P., Cobain, E., Everett, J., Cao, X., Rabban, E., Kumar-Sinha, C., Raymond, V., et al. (2017) · Nature

Cancer Genomics and DiagnosticsGenomics and Rare Diseases

Cited by 863

NCCN Guidelines Insights: Kidney Cancer, Version 2.2020

Motzer, R. J., Jonasch, E., Michaelson, M. D., Nandagopal, L., Gore, J. L., George, S., Alva, A., Haas, N., Harrison, M. R., Plimack, E. R., et al. (2019) · Journal of the National Comprehensive Cancer Network

Renal cell carcinoma treatmentBladder and Urothelial Cancer Treatments

Cited by 287

Amyloid-β 11 C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials

Liu, E., Schmidt, M. E., Margolin, R., Sperling, R., Koeppe, R., Mason, N. S., Klunk, W. E., Mathis, C. A., Salloway, S., Fox, N. C., et al. (2015) · Neurology

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 151

Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies

Graham, L. S., Montgomery, B., Cheng, H. H., Yu, E. Y., Nelson, P. S., Pritchard, C., Erickson, S., Alva, A., & Schweizer, M. T. (2020) · PLOS ONE

Prostate Cancer Treatment and ResearchCancer Immunotherapy and Biomarkers

Cited by 114

Fc glycoengineering of a PD-L1 antibody harnesses Fcγ receptors for increased antitumor efficacy

Cohen Saban, N., Yalin, A., Landsberger, T., Salomon, R., Alva, A., Feferman, T., Amit, I., & Dahan, R. (2023) · Science Immunology

Monoclonal and Polyclonal Antibodies ResearchCancer Immunotherapy and Biomarkers

Cited by 39

Evaluating the reliability of large language models for clinical data extraction in bladder cancer prognosis

Sun, D., Hadjiiski, L., Bruno, G., Gormley, J., Chan, H.-P., Caoili, E. M., Cohan, R. H., Alva, A., Mihalcea, R., Zhou, C., et al. (2025) · Scientific Reports

Machine Learning in HealthcareArtificial Intelligence in Healthcare and Education

Cited by 9